GET DAILY SIGNALSAcrivon Therapeutics (ACRV) Q3 2026 Earnings Preview: What Analysts Expect
Key Takeaways
- Acrivon Therapeutics (NASDAQ: ACRV) is expected to report third-quarter 2026 results around November 12, 2026, with the company's fiscal quarter ending September 30, 2026.
- Wall Street consensus points to a net loss of roughly $0.45 per share, compared with a loss of $0.47 per share in the same quarter a year earlier.
- Revenue expectations remain minimal — near or below $0.5 million — reflecting the company's clinical-stage, pre-commercial status.
- ACRV has beaten consensus earnings per share (EPS) in six of its last eight quarters, including a narrower-than-expected Q2 2026 loss of $0.43 per share.
- Investor attention will likely center on clinical progress for its lead programs, ACR-368 and ACR-2316, plus any update to its cash runway.
Why These Earnings Matter for a Clinical-Stage Biotech
Acrivon Therapeutics is a clinical-stage precision oncology company advancing two drug candidates — ACR-368 and ACR-2316 — toward potentially registrational data. Because the company generates essentially no product revenue, its quarterly report functions less as a traditional income statement and more as a progress check on clinical execution, operating-expense discipline, and, most critically, its cash position. Investors look to these updates to gauge whether the company's research and development (R&D) spending remains on plan and whether its cash reserves are sufficient to fund trials through key data readouts. For a biotech with a market capitalization near $74 million, each earnings release can meaningfully move sentiment.
Consensus Estimates and Historical Beat Record
Analysts expect Acrivon to post a net loss of approximately $0.45 per share for the quarter ended September 30, 2026, according to consensus estimates. Revenue expectations are negligible — generally modeled at about $0.5 million — consistent with a company that has yet to commercialize a product. In the year-ago third quarter, the company reported a loss of $0.47 per share.
The company has a strong record of beating bottom-line expectations, topping consensus EPS in six of its last eight quarters. In its most recent report, for the second quarter of 2026, Acrivon delivered a loss of $0.43 per share, beating the roughly $0.50 consensus estimate on lower-than-expected R&D and general and administrative (G&A) costs tied to clinical-trial timing. A repeat of that expense discipline would be the clearest path to another upside surprise.
Beyond the headline numbers, investors will watch for updates on the ACR-368 Phase 2b trial in endometrial and ovarian cancers, where interim data has shown a confirmed overall response rate (ORR) of 52% in serous endometrial cancer, and on the Phase 1/2 program for ACR-2316 in small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Sentiment Heading Into the Report
Sentiment heading into this report is cautious but focused. ACRV trades at a relatively low valuation, and prior quarters have shown that modest expense beats can translate into favorable post-earnings reactions — the stock has generally drifted following its last release, reflecting a market still waiting on definitive clinical catalysts. The key risks are twofold: any indication that the cash runway is shorter than previously guided, and any delay or setback in the ACR-368 or ACR-2316 programs. Because these are binary, data-driven catalysts rather than revenue-driven results, investors may react more to forward-looking clinical commentary than to the headline loss itself. From what I see, this focus on clinical milestones sets the tone for how the market digests the numbers.
Key Items to Monitor After the Release
After this report, investors should keep a close watch on the company's cash runway. As of the most recent disclosures, Acrivon indicated its cash, cash equivalents, and investments — supplemented by proceeds from an at-the-market (ATM) offering — were expected to fund operations into the latter part of 2027. Any revision to that timeline, in either direction, is likely to be a key driver of near-term sentiment.
On the clinical side, the ACR-368 Phase 2b trial remains the central story. The company has added new trial arms testing ACR-368 in broader serous endometrial cancer populations, with and without a sensitizing agent, and additional interim data could validate or challenge the 52% ORR reported earlier. Progress on ACR-2316, which has shown early signs of tumor shrinkage in lung cancers, offers a second, independent catalyst.
Finally, watch operating-expense trends. The company's ability to keep R&D and G&A spending in line while advancing multiple trials will determine how far its current cash can stretch. For a pre-revenue biotech, disciplined spending and clear clinical milestones — not quarterly revenue — are what ultimately matter most. I’m watching this closely as the data readout timeline approaches.
Using Tickeron Tools in My Research Process
In preparing for this earnings season, I turned to Tickeron’s AI Screener to quickly filter clinical-stage oncology names and compare operating metrics across peers. The tool’s ability to combine fundamentals, technical patterns, and AI signals helped surface relevant context without hours of manual work. It has become a regular part of how I evaluate names like ACRV ahead of catalysts, especially when cash runway and trial timelines are the primary variables. For investors looking to add data-driven screening to their workflow, this approach keeps the focus on the metrics that matter most for pre-commercial biotechs.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ACRV's RSI Indicator ascends from oversold territory
The RSI Indicator for ACRV moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 26 of the 27 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +8.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACRV advanced for three days, in 180 of 203 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
ACRV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ACRV as a result. In 64 of 73 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for ACRV turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 35 similar instances when the indicator turned negative. In 31 of the 35 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
The 10-day moving average for ACRV crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACRV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for ACRV entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 34 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.796) is normal, around the industry mean (3.498). P/E Ratio (-0.856) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. ACRV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACRV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement